Western pharmaceutical companies are no longer seeking cheap 'me-too' assets in China. Instead, they are paying premium prices for genuinely innovative drugs, as evidenced by a 10x increase in deal size over five years and a surge in patent filings from the region.

Many consumers believe that drugs purchased in the US work better than the same drugs in India. However, this is largely a psychological bias. Nearly half of the generic drugs sold in America are manufactured in India, subject to rigorous US regulatory norms, making the products functionally identical.

In the biosimilars industry, where prices inevitably decline over time, full vertical integration (from R&D to commercialization) is essential for survival. By controlling the entire value chain, companies like Biocon avoid profit-sharing with partners, preserving margins and enabling them to withstand market pressures that would cripple less integrated competitors.

Amid debates about high drug prices, it's often overlooked that the existing patent cliff model is highly effective. 90% of all prescriptions in the U.S. are for low-cost generic drugs, demonstrating the system's ability to reduce prices at scale once patent exclusivity ends.

The gap between U.S. and international drug prices is a structural feature of the pharma economy. High profits from the U.S. market fund expensive R&D that ultimately benefits the rest of the world, which pays far less for the same innovations. This reframes the debate around high American healthcare costs.

Contrary to the popular narrative, China doesn't dominate the final API market against India. Instead, China's strategy is to supply low-cost chemical intermediates. Indian firms then perform the final, more complex and profitable conversion steps to create the finished Active Pharmaceutical Ingredient (API).

In a market with many identical branded generics, doctors' prescribing decisions are driven by personal relationships, not product features. Pharma giants employ vast sales forces (10k-17k reps) whose primary job is to visit doctors, build rapport, and convince them to prescribe their version of a drug.

Selling low-cost vaccines to organizations like Gavi isn't just charity for pharmaceutical companies. It creates massive economies of scale, lowering the cost of goods for their high-margin primary markets and increasing overall net profit, creating a powerful win-win incentive structure.

MFN's pressure on global pricing will change how innovation is valued. Truly disruptive drugs may command higher prices ex-US, while incremental "me-too" drugs in crowded classes will not. This will force pharma companies to shift R&D investment away from iterative improvements and toward therapies with radical treatment-disrupting potential.